The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable patients to access oncology therapies that are not routinely publically funded. In April 2016, the CDF became a temporary reimbursement fund under the remit of NICE with the aim of collecting observational data to inform subsequent technology appraisals. This research aims to evaluate how the reformed CDF has been utilised in the two years since its implementation.
Authors: Sean Walsh, Lok Wan Liu, Richard Macaulay
To find out more about this poster you can register to download it here after the ISPOR event.